B2-DNR CAR T / AstraZeneca, Gracell - LARVOL DELTA

Nanobody-based, DLL3-directed FAST-CAR T-cell therapy for small cell lung cancer (SCLC) (AACR 2026) - "The camelid nanobody-derived, DLL3-targeted CAR T-cell therapy manufactured by a 3-day FasTCAR process demonstrates the potential to elicit deep and durable antitumor responses with a favorable safety profile. Preclinical data for the lead candidate, B2‑DNR, support further clinical development for the treatment of SCLC."

CAR T-Cell Therapy • IO biomarker • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3 • TGFB1